Please go ahead, sir. Thank you, operator. Good morning, everyone. And welcome to PDS Biotech's 2024 results and clinical program update call. I am joined on the call today by the following ...

Good morning and welcome to PDS Biotech's 4th quarter in full year 2024 earnings conference call. Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's 2024 results and ...

PDS Biotechnology Corp (PDSB) reported a net loss of $37.6 million for 2024, an improvement from the $42.9 million loss in 2023, during its Q4 2024 earnings call. The company’s efforts to reduce ...

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its ...